Skip to main content

Table 1 Comparison of clinical features between survival group and death group

From: Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients

 

Total patients (n = 90)

Survival group (n = 68)

Death group (n = 22)

P value

Demographic features

    

Female, n (%)

57 (63.3)

43 (63.2)

14 (63.6)

0.973

Age, years, mean ± SD

51.9 ± 12.1

49.5 ± 11.4

59.2 ± 11.6

0.001*

Disease duration, months, median (IQR)

2.0 (1.0, 3.8)

2.0 (1.0, 4.0)

1.0 (1.0, 2.8)

0.086

Clinical features

    

CADM, n (%)

70 (77.8)

51 (75.0)

19 (86.4)

0.380

Raynaud’s phenomenon, n (%)

9 (10.0)

7 (10.3)

2 (9.1)

1.000

Gottron’s papules, n (%)

61 (67.8)

46 (67.6)

15 (68.2)

1.000

Skin ulcer, n (%)

2 (2.2)

1 (1.5)

1 (4.5)

0.431

Laboratory test

    

Serum ferritin, ng/ml, median (IQR)

875.0 (538.2, 1794.2)

734.5 (426.2, 1255.5)

2198.5 (1008.8, 2923.5)

 < 0.001*

KL-6, U/ml, median (IQR)

939.5 (654.2, 1362.5)

857.0 (640.8, 1202.2)

1736.0 (830.0, 2958.5)

0.002*

CK, U/L, median (IQR)

64.5 (34.2, 122.5)

64.5 (34.0, 114.5)

72.5 (41.8, 132.2)

0.508

CRP, mg/L, median (IQR)

6.4 (2.8, 21.8)

4.4 (1.7, 16.5)

23.0 (11.2, 44.7)

 < 0.001*

ESR, mm/h, median (IQR)

32.0 (22.0, 48.0)

30.5 (19.8, 45.0)

37.0 (27.2, 71.8)

0.043*

Lymphocyte, × 109/L, median (IQR)

0.7 (0.6, 1.1)

0.8 (0.6, 1.2)

0.6 (0.4, 0.9)

0.014*

Anti-Ro52, n (%)

64 (71.1)

44 (64.7)

20 (90.9)

0.018*

Anti-MDA5, U/ml, median (IQR)

188.5 (158.5, 206.3)

187.5 (155.5, 206.0)

192.3 (165.8, 205.0)

0.333

ANA ≥ 1:320, n (%)

15 (16.7)

11 (16.2)

4 (18.2)

1.000

HRCT findings

    

Total CT GGO score, median (IQR)

2.0 (0.0, 7.8)

0.5 (0.0, 4.0)

11.0 (5.0, 14.8)

 < 0.001*

Total CT fibrosis score, median (IQR)

2.0 (1.0, 6.0)

2.0 (0.0, 4.0)

6.0 (2.2, 12.0)

0.001*

Treatment

    

Initial combination therapy, n (%)

58 (64.4)

53 (77.9)

5 (22.7)

 < 0.001*

IVIG, n (%)

43 (47.8)

31 (45.6)

12 (54.5)

0.465

  1. CADM, clinically amyopathic dermatomyositis; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; anti-MDA5, anti-melanoma differentiation-associated protein-5; ANA, anti-nuclear antibody; HRCT, high-resolution CT; GGO, ground-glass opacity; CNI, calcineurin inhibitors; CYC, cyclophosphamide; IVIG, intravenous immunoglobulin; SD, standard deviation; IQR, interquartile range
  2. *Significant
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172